Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Argenx Se ADR (NQ: ARGX ) 391.90 +8.56 (+2.23%) Streaming Delayed Price Updated: 2:54 PM EDT, May 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 116,737 Open 387.38 Bid (Size) 391.26 (4) Ask (Size) 392.02 (2) Prev. Close 383.34 Today's Range 384.25 - 391.90 52wk Range 327.73 - 550.76 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024 Today 1:00 EDT From argenx SE Via GlobeNewswire The Analyst Verdict: argenx In The Eyes Of 12 Experts April 18, 2024 Via Benzinga Performance YTD +2.86% +2.86% 1 Month -1.37% -1.37% 3 Month +2.99% +2.99% 6 Month -20.79% -20.79% 1 Year -0.22% -0.22% More News Read More argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease April 16, 2024 From argenx SE Via GlobeNewswire Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy April 10, 2024 Via Benzinga argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease March 27, 2024 From argenx SE Via GlobeNewswire Key Takeaways From argenx Analyst Ratings March 26, 2024 Via Benzinga Earnings Scheduled For February 29, 2024 February 29, 2024 Via Benzinga argenx Announces Annual General Meeting of Shareholders on May 7, 2024 March 26, 2024 From argenx SE Via GlobeNewswire Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday March 26, 2024 Via Benzinga argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia March 26, 2024 From argenx SE Via GlobeNewswire Guess? Posts Upbeat Earnings, Joins Lufax, Nortech Systems And Other Big Stocks Moving Higher On Thursday March 21, 2024 Via Benzinga Topics Stocks Exposures US Equities Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session March 21, 2024 Via Benzinga Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday? March 21, 2024 Via Benzinga Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results March 21, 2024 Via Investor's Business Daily 12 Health Care Stocks Moving In Thursday's Pre-Market Session March 21, 2024 Via Benzinga Why Micron Therapies Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket March 21, 2024 Via Benzinga argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting March 07, 2024 From argenx SE Via GlobeNewswire argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update February 29, 2024 From argenx SE Via GlobeNewswire argenx to Present at Upcoming Investor Conferences February 26, 2024 From argenx SE Via GlobeNewswire argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024 February 22, 2024 From argenx SE Via GlobeNewswire 3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition February 21, 2024 Via InvestorPlace argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy February 20, 2024 From argenx SE Via GlobeNewswire 5 medical stocks growing earnings by triple digits February 06, 2024 Via MarketBeat Topics Economy Exposures Economy New Hope For Patients With Chronic Autoimmune Conditions: Johnson & Johnson's Investigational Drug Meets Primary Goal In Two Studies February 05, 2024 Via Benzinga Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion January 18, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
